New Zealand Expands Mpox Vaccine Access Following Medsafe Approval

"While the overall risk of mpox in New Zealand remains low, it is crucial that we respond appropriately to this global public health concern," said Dr. Reti.

The New Zealand Government is taking swift action to enhance the country’s response to mpox, with a focus on improving vaccine access for those most at risk, Health Minister Dr. Shane Reti and Associate Health Minister David Seymour announced today.

"While the overall risk of mpox in New Zealand remains low, it is crucial that we respond appropriately to this global public health concern," said Dr. Reti.

The vaccine Jynneos, previously available under specific provisions since 2023, has now been granted provisional approval by Medsafe. This move will allow greater access to the vaccine for those in need.

"This decision aligns New Zealand with other countries that have approved the use of Jynneos. In Australia, for instance, the vaccine is available under an exemption," said Mr. Seymour.

Medsafe's approval, based on information from Health New Zealand, confirms that the vaccine meets the required standards for safety, efficacy, and quality for groups at risk of mpox. Health New Zealand played a key role in facilitating the approval process.

Dr. Reti also confirmed two cases of mpox with likely connections to the Winter Pride Festival, with ongoing investigations that may reveal more cases. Despite these cases, the overall risk to the public remains low.

An Incident Management Team has been activated at the national level to coordinate the public health response, while regional teams continue to manage case support and treatment. The focus is on minimizing the spread of mpox through preventative measures and public awareness efforts.

Health agencies are urging those with symptoms to seek advice from sexual health clinics and healthcare professionals, and to avoid sexual activity until they are cleared.

The next step will involve the National Immunisation Technical Advisory Group reviewing which groups are most at risk and should receive the vaccine now that provisional approval has been secured.